AxoGen, Inc.

NASDAQ:AXGN

Medical - Devices

Healthcare
$56.95 +0.56%

+$0.25 today

Market cap
$3.40B
Beta
1.12
P/E (TTM)
-73.4
EPS (TTM)
-$0.61
52W Low $9.35High $45.83

Volume 2.11M

Average 1.08M

AXGN Long-term Debt

Borrowings due after more than one year.

AxoGen, Inc.NASDAQ: AXGN

Long-term Debt · Q3 FY2026 · quarter ended Sep 2026

Long-term debt remains negative

Q3 FY2026 long-term debt was $0, compared with $48.16M a year earlier. Over 3 fiscal years it compounded at +1.9% a year.

Context

  • Long-term debt amounted to 0.0% of total assets at the end of Q3 FY2026, down 22.3 pp from a year earlier.
  • Long-term debt increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$48.39M+1.9% YoY
Year agoSep 2025
$48.16M-100.0% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+1.9%——
3-year CAGR+1.9%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
48.39M USD
Year-over-year change
+1.9%
4-year CAGR
+1.9%

Long-term Debt vs competitors

How AXGN compares with its peers on the latest reported figures

  • AXGN's Sep 2026 long-term debt of $0 is the 6th highest of the 7 companies compared; the peer median is $12.09M.
  • Its year-over-year change of -100.0% is the lowest of 6, against a peer median of -44.5%.
  • Long-term debt amounts to 0.0% of total assets for AXGN, versus a peer median of 7.8%.
AXGN Competitors Peer median
Long-term Debt for AXGN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TELATELA Bio, Inc.Jun 2026$56.08M +47.4%+11.7%93.9%
HUMAHumacyte, Inc.Mar 2026$35.87M -44.5%+20.3%32.4%
MDXGMiMedx Group, Inc.Mar 2026$16.09M -8.2%-30.3%5.2%
XTNTXtant Medical Holdings, Inc.Mar 2026$8.1M -63.5%+4.4%10.4%
BSEMBioStem Technologies, Inc.Jun 2026$1.36K -99.1%—0.0%
AXGNAxoGen, Inc.Sep 2026$0 -100.0%+1.9%0.0%
ORGOOrganogenesis Holdings Inc.Mar 2026$0 —-8.5%0.0%
Peer median (excluding AXGN) $12.09M-44.5%+4.4%7.8%

Competitors are the stored peer set for AXGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents32.76M15.28M31.02M27.55M35.55M
Short-term Investments51.33M33.51M05.93M0
Net Receivables18.16M22.19M25.15M24.11M26.17M
Inventory16.69M18.91M23.02M33.18M42.37M
Other Current Assets6.25M6.25M6M8.45M16.33M
Total Current Assets127.05M98.08M88M99.22M120.42M
Property, Plant & Equipment (Net)78.12M93.66M104.29M98.93M94.52M
Goodwill00000
Intangible Assets2.86M3.65M4.53M5.58M6.75M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets80.98M97.31M108.82M104.51M101.27M
Total Assets208.02M195.39M196.83M203.73M221.69M
Account Payables5.92M8.96M11.77M8.01M2.89M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities9.67M0018.58M16.63M
Total Current Liabilities24.29M23.75M30.43M30.61M23.56M
Long-term Debt44.82M45.71M46.6M47.5M48.39M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities5.56M4.52M2.99M2.49M4.03M
Total Non-current Liabilities71.18M70.64M70.73M69.21M69.28M
Total Liabilities95.47M94.39M101.16M99.82M92.84M
Common Stock417K424K431K441K472K
Retained Earnings(230.63M)(259.58M)(281.3M)(291.26M)(306.96M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity112.55M101M95.67M103.91M128.85M
Total Debt67.45M67.43M69.29M68.69M67.63M
Net Debt34.7M52.14M38.27M41.13M32.08M

AxoGen, Inc.

NASDAQ:AXGN

Intrinsic Alpha fair value

Locked

Current Price

$56.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.